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Introduction 
Objective 
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Social inequalities in cancer outcomes are well documented. The social 
determinants of these cancer disparities often include factors related to race, age, gender, 
social capital, socio-economic status, and environment. These determinants often work in 
combination to create or help sustain the disparities in cancer outcomes that appear to be 
widespread in the United States. One of the ways that social determinants create 
inequalities is by promoting differences in the quality of cancer treatment for different 
patient subgroups. For instance, there is some evidence that colon cancer patients who 
belong to disadvantaged races, who live in rural areas, or who have low socio-economic 
status receive recommended adjuvant chemotherapy (ACT) at lower rates than 
predominant social groups. 14 However, studies examining the link between these social 
factors and the quality of cancer treatment often offer conflicting results. 5 
This study examines the relationship between living in rural areas and the receipt 
of adjuvant chemotherapy for colon cancer patients in North Carolina. It also examines 
the relationship between region of residence in North Carolina and the probability of 
ACT receipt. Patient-level data was acquired from the North Carolina Central Cancer 
Registry (CCR) to answer the study questions. If a treatment disparity is found it may 
indicate the need for specific interventions to counter deficiencies in post-operative 
medical care for rural patients with colon cancer. 
Burden of Disease 
Colorectal cancer is the third most frequent cancer type and the third leading 
cause of cancer death in the United States.6 The American Cancer Society projected that 
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colon cancer, a subtype of colorectal cancer, was diagnosed in over one hundred 
thousand Americans in 2007 and that nearly 52,000 cases died last year.6 These numbers 
are estimates of the burden of disease, but they are calculated with incidence data from 
the Surveillance Epidemiology and End Results (SEER) database. The SEER database is 
the most comprehensive database describing annual incidence of the most common forms 
of cancer affecting Americans. 
The American Cancer society derives its cancer mortality figures from the 
National Center for Health Statistics (NCHS).6 Together, raw data from SEER and the 
NCHS provide the best estimates of national cancer statistics available. Estimates of 
disease burden in North Carolina also come from come from the North Carolina Central 
Cancer Registry (CCR).7 Using similar techniques as the ACS, the registry estimated that 
4,425 new cases and 1,645 deaths from colorectal cancer occurred in North Carolina in 
2007.7 
Treatment of Colon Cancer 
Surgery is the primary therapy for colon cancer. All patients with stage I to stage 
III colon cancer (85% of cases) require surgical removal as the major mode of therapy. 8 
Adjuvant chemotherapy is recommended for patients with stage III cancer.9 These cases 
comprise 22% of all incident colon cancers. The recommended chemotherapy regimen 
was initially based on results from three clinical trials indicating that 5-fluorouracil and 
levarnisole improved five-year survival in patients with stage III colon cancer compared 
to those who received levisimole alone, or surgery alone. 9 In particular, adjuvant 
chemotherapy lowers five-year mortality by 33% and five-year recurrence by 40% when 
compared to surgery alone.10 
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In 2003 fluorouracil plus leucovorin became the standard therapy following a 
series of trials proving its superiority to fluorouracil and levamisole. In 2004, Andre et 
al. demonstrated that adding oxaliplatin to fluorouracil and leucovorin improves five-year 
survival from 73%, to 78%. These results led to oxaliplatin gaining acceptance as the 
current standard adjuvant chemotherapy treatment.9 The results of adjuvant 
chemotherapy appear even more impressive when one considers an outcomes table 
(Table 1 ). As seen in Table 1, stage III colon cancer patients on average have mortality 
rates reaching 55% over 5 years with only surgery, but with adjuvant chemotherapy five-
year mortality may fall to as low as 36.6%.8•10 Combining the figures derived by the 
ACS and by Moertel et. al, one can estimate that there are nearly twenty-two thousand 
patients are diagnosed with stage III cancer a year in the U.S. One can postulate that if 
these patients are treated with surgical resection alone, on average 12,100 will die within 
five years. 8 Providing adjuvant chemotherapy to all eligible candidates may lower this 
number to 8,066 over five years. 
In the context of clinical trials, ACT has offered impressive survival benefits for 
stage III patients. Consequently, adjuvant chemotherapy has gained nationwide 
acceptance as critical part of post-operative colon cancer treatment. The National Cancer 
Institute and the National Institute of Health both have issued recommendations 
reiterating this point, but U.S. cancer patients have experienced low treatment rates for 
nearly a decade. In 2001, Schrag et al. concluded that only 55% of eligible Medicare 
patients received adjuvant treatment. 11 Similarly, in 2004, the investigators recording 
data for the National Cancer Database found that only 45% of eligible patients received 
adjuvant chemotherapy. More recent figures for all colon cancer patients indicate that 
5 
these numbers are on an upward trend, as some demographic groups receive ACT at rates 
close to 80%, but under-treatment is still present, especially among certain subgroups.12 
Disparities in Treatment among Colon Cancer Patients 
Race 
Several studies have explored social factors explaining why some groups receive 
adjuvant chemotherapy at lower rates than the average and key results have surfaced. 
Race, age, rural residence, insurance status, socioeconomic status have all been found to 
be related to the under use of adjuvant chemotherapy, but results have been conflicting 
for some of these factors. Most recent studies have found no relationship between race 
and rates of adjuvant chemotherapy use.1• 2• 12 The most recent study to find otherwise, 
Baldwin eta!., noted that African American patients were just as likely to be offered 
chemotherapy, but significantly less likely to receive it. 13 This result might indicate 
differences in patient preference, a problem with physician-patient communication, or 
problems with access to care for certain racial groups. This is an area which needs 
further research, but preliminary results indicate that white and black patients may be 
offered ACT for colon cancer at similar rates. 
Socio-economic Status and Insurance Status 
Only one study has found that insurance status and income are related the receipt 
of adjuvant chemotherapy among colon cancer patients. In 2002, in a study by 
VanEnwyk, patients with an annual income ofless than nine thousand dollars were 
significantly less likely to receive adjuvant chemotherapy. The study also found that 
patients with private insurance were more likely to receive adjuvant chemotherapy than 
patients with Medicare or Medicaid, but the study was unable to control for other factors 
like education level, and the measure of insurance status was inexact. Given the 
weaknesses in this study and the lack of available evidence on the subject, the 
relationship between socio-economic status, insurance status and colon cancer treatment 
is inconclusive. 5 
Age 
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Studies have consistently linked advanced age at cancer diagnosis to low rates of 
adjuvant chemotherapy receipt. One study estimated that only 69% of patients between 
the ages of70 and 79 receive ACT treatment, while only 34% above age 80 receive 
ACT. 11 Another study published in 2002, found that patients younger than 55 were much 
more likely to receive adjuvant chemotherapy than patients older than 80 after adjusting 
for co-morbidities.5 
There are several possible reasons for this trend. First, the presence of significant 
co-morbidities among the elderly could play a role. Potosky et al. found that the presence 
of a co-morbidity using the Charlson co-morbidity scale was inversely related to the 
receipt of standard adjuvant chemotherapy when adjusting for age.14 The Charlson 
morbidity score measures the severity of co-morbid conditions, with higher scores 
representing more significant health problems. A score of zero represents the healthiest 
patients and a score of three or more three represents the sickest patients. A more recent 
study, published in 2006, using SEER data found that 60% of elderly patients ( age>65) 
with a score of zero received adjuvant chemotherapy, while only 51% and 45% of 
patients with scores of two and three were offered treatment.15 
Physician reluctance to prescribe the current adjuvant chemotherapy regimen to 
patients with several co-morbidities may be well-founded, because randomized controlled 
trials describing the efficacy of each treatment rarely included patients with significant 
co-morbidities.9 Consequently, it is not known whether co-morbidities reduce the 
survival benefits offered by adjuvant chemotherapy for colon cancer. 
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In addition, some physicians may not offer elderly patients chemotherapy because 
of notions that otherwise healthy elderly patients cannot significantly benefit from 
chemotherapy. Physicians may believe that the elderly have low potential life expectancy 
or may believe that the elderly do not tolerate chemotherapy well. Studies among the 
elderly examining these issues are limited in number, but Sargeant eta!. published a high-
quality study in 2001 indicating that patients taking 5-fluorouracil experienced higher 
rates of severe organ toxicity and poorer patient tolerability when compared to patients 
under 65. 14 This study seemed to validate the belief that patient tolerability of 
chemotherapy declines with age, independent of general health. On the other hand, 
Jensen eta!. in 2006 found that patients 75 years and older, despite requiring lower doses 
of chemotherapy, still benefited significantly from adjuvant treatment.15 Furthermore, 
Jessup et a! found in 2005 that colon cancer patients 80 years or older benefited similarly 
from adjuvant chemotherapy in terms of five-year survival in comparison to younger 
patients.12 Consequently, age is currently not accepted as a reason for not offering 
adjuvant chemotherapy to patients with stage III colon cancer, but physicians must be 
prepared to vary doses to optimize patient tolerance. 
Finally, patient age may relate to patient preference for treatment. In a study of 
general patient preferences for adjuvant chemotherapy, age was a strong predictor of 
patient preference with older patients less likely to choose ACT. 16 It is difficult to 
estimate how much patient preference for treatment is responsible for age's effect on the 
receipt of adjuvant chemotherapy. A patient's preference against ACT could explain 
much of the differences seen in the receipt of ACT among older cancer patients. 
However, research suggests that patients rely heavily on the advice of physicians; better-
informed physician advice may lead to a reduction of the age gap in cancer therapy. 
Rural Residence 
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Only a few studies have examined the relationship between rurality and ACT 
receipt. One study done by V anEenwyk et a!, in 2002 indicated that patients living in 
rural zip codes in Washington State were 60% less likely to receive adjuvant 
chemotherapy. The authors were able to adjust for patient co-morbidity, age, sex, race 
and insurance status. 5 The data used in this study included colon cancer cases diagnosed 
from 1996 to 1997. Research has suggested that rates of adjuvant chemotherapy for 
patients with stage III colon cancer have continued to increase since the mid 1990's, so 
the results of this study may not adequately reflect the current relationship between rural 
residence and ACT receipt. 12 A second study done by Wu et. a!, in 2004, using data from 
several Louisiana hospitals and medical practices, found no difference in the receipt of 
ACT between patients living in rural versus urban areas. The authors of this study 
controlled for confounding factors thoroughly, and their results provide up to date 
information regarding rurality's effect on ACT receipt. 17 More studies are needed to 
verifY the results put forth by Wu's study. 
Research Objective 
We will attempt to investigate the relationship between rural residence and ACT 
receipt for stage III colon cancer cases using data from the North Carolina Central Cancer 
Registry (CCR). This is a worthwhile study to undertake given that there are few studies 
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examining the study question we propose, and the studies that have been published offer 
conflicting results. Additionally, the breadth of information obtainable from the CCR has 
been improved significantly over the years, and we hope we can answer our study 
questions adequately and also provide information about regional differences in ACT 
receipt. The CCR now obtains a higher percentage of information about colon cancer 
cases in the state than in past years, especially from small community hospitals. The CCR 
has also added variables related to patient refusal of treatment, and more detailed 
information about tumor stage, grade and date of treatment. 
One of the most difficult challenges of this study is adequately defining rural 
residence. Depending on one's definition of rurality, around I 0- 28% of the U.S. 
population lives in rural areas. 18• 19 On average residents in rural areas in the U.S. have 
higher rates of unemployment, higher percentages of the elderly and of children, lower 
population density, higher poverty rates, and higher rates of uninsurance and 
underinsurance.18 Many of these characteristics of rural environments play a role in the 
quality of care patients receive. The prevalence of these factors varies depending on the 
definition of urbanization that researchers use. 
Using rural residence as an independent variable in analytic studies leads to two 
major problems. The first is that rural areas can vary greatly in terms of culture, 
economics, demography and environment. As a result, attempting to lump all rural areas 
together in these types of analyses is difficult and ultimately leads to a more diverse 
groups that desired. 18 A second problem relates to the possibility that a defined level of 
urbanization serves only as a marker for more specific social determinants of health. The 
factors that truly affect health outcomes in rural areas may be classified more clearly by 
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reporting population density, economic and trade development, environment, pollution, 
urbanization, relationship to metropolitan areas, penetration and development of medical 
specialists, or distance to hospital care.18 As a result, it is useful for researchers to also 
attempt to evaluate these other variables by either controlling for them or evaluating them 
individually and including them in the study discussion. 
Despite these difficulties, a number of standardized methods for defining 
urbanization have emerged. The Office of Management and Budget (OMB) has issued 
one of the more widely accepted systems of defining urbanization. 17• 18 The OMB system 
is based on assigning all U.S. counties Urban Influence Codes, which were derived from 
2000 census figures. These codes classify counties as either metropolitan or non-
metropolitan based on population size, population density and proximity to urban areas. 
This system then subdivides each category based on adjacency to the different size 
counties created. 19 The Urban Influence Codes put forth by the OMB offer one of most 
rigorous and conservative methods of delineating rural areas as has been used in many 
studies in heath care research. 18 
Consequently, we will use OMB urban influence codes in our analysis. We will 
also examine the relationship between patient region of residence and the receipt of 
adjuvant chemotherapy, to determine whether there are regions of the state with lower 
receipt of ACT, regardless of degree of rurality. We believe that these relationships will 
clearly delineate whether access to care represents a barrier to the receipt of 
chemotherapy. We will attempt to control for the other factors that are related to rural 
residence and receipt of ACT. 
Methods 
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Data source 
The North Carolina Central Cancer Registry (CCR) collects information on colon 
cancer cases diagnosed and treated within state boundaries. The CCR records name, 
gender, age, sex, race/ethnicity, insurance status, and residence geocodes. The CCR also 
collects information related to disease, including tumor stage, tumor grade, date of 
diagnosis, initial treatment, use of adjuvant chemotherapy and patient specified reason for 
refusing treatment. The CCR is licensed to receive information from every cancer 
diagnosing health care provider within the state. The sources of information most often 
are hospital based, but they can include physician practices, pathology laboratories and 
individual death certificates. The goal of the CCR is to monitor the incidence of cancer 
among various populations over time, and to also report information related to staging, 
location and treatment. Specifically for colon cancer the CCR obtains over 83% of the 
desired information. Public health experts, researchers, and members of the state health 
department analyze the data upon request. The quality of the data is assessed and by the 
NCCCR, Centers for Disease Control and the North American Association of Central 
Cancer Registries. 
Patients 
Our analysis was restricted to state residents diagnosed with colon cancer between 
1998 and 2004 in North Carolina. The study included all men and women diagnosed with 
stage III colon cancer in that time. Staging was accomplished using the tumor, node, 
metastases staging classification designated by the American Joint Cancer Commission 
(AJCC). The patients were staged from physical exam, abdominal and chest CT, and 
intra-operatively. Stage III according to the AJCC includes all patients with colon cancer 
extending to one or two lymph nodes but without established metastasis. All patients 
meeting these criteria were included in the study.Z0 
Geocoding Locations 
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We used Geographic Information Systems (GIS) to provide spatial analysis. Our 
goal was to accurately determine each patient's residence within a North Carolina county. 
Traditionally, GIS has been a powerful research tool allowing investigators to process, 
analyze and visualize ecologic data. In this study, as part of the abstraction of process, 
the CCR collected information on patient residence. Through GIS, the CCR was able to 
give each patient a geo-code for residence location. Using these geo-codes, the CCR 
assigns each patient to a specific county in North Carolina. The CCR is also able to 
assign a geo-code location for a patient's hospital of diagnosis, surgical treatment and 
adjuvant chemotherapy treatment. We will use the patient's geocoded data on residence 
to determine the patient's county urbanization level and geographical region. We will 
examine the relationships between these factors and the probability of receiving 
recommended adjuvant chemotherapy and other factors related to receiving appropriate 
care. 
Study Variables 
Urbanization 
Rural status was defined using urban influence codes which were published by the 
federal Office of Management and Budget (OMB) in 2003. We grouped the OMB's 
codes to fit the design of our study. The urban influence codes originally defined by the 
OMB can be seen in Table 2. The listed classification scheme defines metropolitan 
counties and then divides the remaining non-metropolitan counties by their size and 
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adjacency with more urbanized areas. The urbanization scale correlates well with 
economic development, access to information, finance and many other important social 
resources. This scale is particularly useful in health access research because the level of 
urbanization and adjacency to urban areas often correlates well with the proximity of 
community hospitals and large medical centers. Using this scale, 75% of the nation's 
land is considered rural, and 17% of the nation's citizens are considered rural residents. 19 
Urban influence codes divide all state counties into a total of 12 groups. As 
mentioned above, counties are first determined to be either metropolitan (metro) or non-
metropolitan. Metro areas are defined using population and commuting data from the 
2000 census. The definition depends on the census definition of an urbanized area. The 
census bureau defines urban areas as those with a nucleus of at least 50,000 residents, 
which may or may not contain individual cities. In general, urban areas must have a 
population density of 1,000 persons per square mile and may contain adjoining territory 
with at least 500 persons per square mile.19 
According to the OMB counties are counted as metro areas if they are central 
counties with one or more urbanized areas, or they outlying counties that are 
economically tied to the core counties by work commuting. Outlying counties are 
included if at least 25 percent of workers living in the county commute to the central 
counties, or if 25 percent of the employment in the county consists of workers coming 
from the central counties. Metropolitan areas are further divided into two groups by their 
population size. Large metro areas are those with more than a million people, and small 
metro areas have less than one million residents. 19 
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Non-metro counties are divided into two main groups. The first group is entitled 
micropolitan (micro) areas which consist of any non-metropolitan area with an urban 
cluster of at least 10,000 residents. Surrounding counties can be included in the micro 
area by considering the amount of inter-county commuting, which is defined in the same 
way as for metro areas which is detailed above. These micro areas are further divided into 
three groups depending on their adjacency or non-adjacency to large, small, or no metro 
areas. The second group of non-metro counties is called non-core counties. They are 
divided into seven groups by their adjacency to a metro or a micro area and whether or 
not they contain a town of at least 2,500 residents. Non-core counties containing more 
than 2,500 resident are referred to as having their "own town".19 
Using patient geo-codes for county residence each patient was placed in one of 
the 12 areas detailed above and also illustrated in Table 2. For the purposes of this study, 
we consolidated urban influence codes into three groups. 1) NC Metropolitan Areas 
which were any area designated as metro using UIC codes (UIC codes 1 and 2). 2) NC 
Non-metropolitan areas were areas designated as non-metropolitan according to UIC 
codes and non-adjacent to metropolitan areas (UIC codes 8-12). 3) NC Adjacent areas 
were defined as areas with UIC codes indicating a non-metropolitan status but areas 
adjacent to metro areas (UIC codes 3-7). The UIC coded regions were grouped in order 
to capture the proximity to metropolitan areas. We believe that the distance each patient 
encountered in attempting to reach a metropolitan area is the most relevant factor to 
explore in regards receipt of chemotherapy. 
North Carolina Region 
15 
The North Carolina Cancer Partnership, an organization committed to the 
improvement of cancer outcomes for patients in North Carolina, divided the state into 
several regions based geography and each region's perceived major center of health care. 
The regions are as follows: the Asheville Region, Greensboro Region, Charlotte Region, 
Raleigh Region, Wilmington Region, and Greenville Region. The counties of each region 
are depicted in Figure 1. We will use patient geo-codes to stratify patient residence based 
on the region in which they live. We will then analyze patient region versus the 
probability of not receiving adjuvant chemotherapy and the other outcomes we outline 
below 
Receipt of care 
We will use several variables to provide information about the receipt of adjuvant 
chemotherapy among the study population. The NC Central Cancer Registry collects 
information on whether patients with stage III colon cancer receive chemotherapy. 
Patients for whom there is no record of chemotherapy having been received are assigned 
one of the following codes: chemotherapy not recommended (1 ); chemotherapy 
contraindicated (2); chemotherapy treatment of choice, not administered, no reason given 
(6), chemotherapy refused by patient, family member or guardian (7); chemotherapy 
recommended, unknown if given (8); and reason for no chemotherapy unknown (9). 
We grouped these variables to create several new variables, to give us a more complete 
picture of whether patients were being offered and receiving care consistent with current 
guidelines. We considered it to be consistent with current guidelines to withhold 
chemotherapy if it was contraindicated or refused by the patient; we therefore created a 
variable "received adjuvant chemotherapy if not contraindicated or refused" that includes 
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patients who received chemotherapy and those for whom chemotherapy was 
contraindicated or refused (codes 2 and 7). We also created a variable "offered adjuvant 
chemotherapy if not contraindicated," which includes those patients who received 
chemotherapy, those to whom chemotherapy was offered but for whom there was 
incomplete data on whether it was received (codes 6 and 8), and those for whom 
chemotherapy was contraindicated or refused (codes 2 and 7). We compared these 
variables to "chemotherapy not recommended," a group for whom it could be clearly 
determined that care was not consistent with current guidelines. 
Statistical Analysis 
Statistical analyses were performed with the help of several biostatisticians at the 
North Carolina Central Cancer Registry. We used the total number of cases of Stage III 
colon cancer occurring between 1998 and 2004 as our study population. We geocoded to 
a specific street address. We geocoded patients who provided non-street addresses to 
census block groups. Finally, we geocoded patients who provided county of residence 
data only. It is important assign as many patients to street level addresses as possible to 
be able to control for some of the confounding variables we will detail below. 
In our analysis, we compared patient residence in Metropolitan Areas, Non-
Metropolitan Areas, and Adjacent Areas to the receipt of adjuvant chemotherapy. We 
compared region of residence using NC Cancer Partnership regions to the receipt of 
ACT. Specifically we used Chi-square analysis to examine our primary and secondary 
questions in the study. We had concerns that the data were not normally distributed and 
we felt that a chi-square test for statistical significance would provide a more valid result. 
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We will also perform multivariate analysis to determine the effect of that the 
potentially confounding variables. Because we did not have patient-level data on income 
we used mean census tract income as a proxy for patient income. For patients for whom 
a street address was not available, we used median county income as a proxy for patient 
income. Those variables will include race, patient age at diagnosis, and sex. We will use 
mean census tract income as crude measure to control for patient income. 
Results 
The North Carolina Central Cancer registry reported that 5,474 patients were 
diagnosed with colon cancer in North Carolina between 1999 and 2004. Of these 5,306 
patients were designated as state residents. The remaining 169 cases were eliminated 
from the study. Demographic characteristics of original sample of patients can be seen in 
Table 3. Of the 5,306 patients who were North Carolina residents, the registry had data 
on chemotherapy treatment and county of residence for 4,432 of the patients diagnosed 
with colon cancer in the time period, and as Table 4 shows, these patients were included 
in the study. This was 83.5% of the North Carolina patients diagnosed with Stage III 
colon cancer. For the remaining 874 patients, the registry did not have adequate treatment 
data. It is unknown how or if these patients were managed. Consequently, they were not 
included in the study. Depending on how these patients were dispersed in the state and 
the treatments they received, they could have affected the results of our analysis 
significantly. 
Geocoding Results 
The geocoded results were originally completed for patients diagnosed with colon 
cancer in North Carolina. Of the 5,306 patients geocoded, only 4945 had treatment data 
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on available to the NCCR. Only these cases were included in the final analyses. Of the 
cases diagnosed among North Carolina residents, the North Carolina Central registry had 
a unique recorded address for 4740 cases. If the cases provided a valid street address they 
were geocoded to that address. If the cases provided a post office box as an address they 
were geocoded to a 2000 census census block group. This step allowed us to better 
classifY their location within their listed county. The remaining cases, 566 or I 0% of the 
total, could not be geocoded to either street address or census block group, so they were 
geocoded to their residential county. 
Care received results 
A total of2,582 patients with Stage III colon cancer received ACT between 1998 
and 2004. This represented 58% of the study population. Twenty-eight percent of the 
patients did not receive a recommendation for ACT, without any indication that ACT was 
contraindicated or refused. A total of 72% of the study population patients was offered 
ACT if it was not contraindicated, and 63% received chemotherapy if it was not 
contraindicated or refused (Table 5). Consequently, the majority of patients in North 
Carolina received care consistent with current treatment recommendations, and a larger 
percentage were at least offered ACT when appropriate, although we do not have 
complete data on whether they received it or the reasons for why they did not receive it. 
For the patients who did not receive ACT, we have some data that sheds some 
light onto the possible reasons. Three patients in the study population died prior to the 
decision to treat or not treat with adjuvant chemotherapy. This was less than 0.01% of the 
study population and was not likely a significant factor in the interpretation of the results. 
For one percent of patients, ACT was contraindicated due to another medical illness. For 
19 
272 patients, 6.1% of the study population, treatment was recommended and either not 
given or it is unknown if treatment was given. 
Chemotherapy regimen results 
The exact chemotherapy regimen received by each patient remains unknown. The 
drugs were not recorded by members of the NCCCR, but they did record the number of 
agents each patient received. Based on the prevalent recommendations at the time, 
patients should have received at least two chemotherapeutic agents to maximally benefit 
from adjuvant chemotherapy.9 In the study population, it is known that nearly 55.3% of 
treated patients received only one chemotherapeutic agent. Only 16.6% of patients 
received two or more chemotherapeutic agents and the regimen. This suggests 
significant under-treatment among even those who received adjuvant chemotherapy. 
Additionally, the data indicates that there is significant heterogeneity of treatment 
received by patients in the study population. It is unknown whether the appropriate 
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chemotherapeutic drugs were administered at appropriate doses in a timely manner. 
Level of urbanization vs. Receipt of Care 
The results describing the relationship between receiving appropriate care and 
urbanization level are listed in Table 6. As described earlier, urbanization level was 
divided into three groups based on metropolitan status or proximity to a metropolitan 
area. On all statistical analyses a chi-square analysis was used due to Non-Gaussian 
distribution of data. 
Patients living in metropolitan areas, non-metropolitan/adjacent areas, and non-
metropolitan/non-adjacent areas received ACT at very similar rates (59.0%, 58.3%, 
54.4%) and chi-square analyses revealed no significant differences between groups 
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(p=0.37). The rates of receiving ACT if not refused or contraindicated (63. 7%, 61.3%, 
55.5%) and being offered ACT if not contraindicated (72.9, 71.3, 70.1) were very similar 
as well and no significant difference with discernable on univariate or multivariate 
analysis. 
Region vs. receipt of care 
The results describing the relationship between region of residence and treatment 
can be seen in Table 7. Again, North Carolina was divided into six regions in this 
analysis: Asheville, Charlotte, Greensboro, Greenville, Raleigh and Wilmington areas 
(Figure 1 ). Patients in Asheville, Charlotte and Greenville were less likely to receive, 
ACT and to be offered ACT than patients in the other NC regions. The relationship 
between treatment and region was statistically significant (p<O. 0001) on the univariate 
analysis. On multivariate analysis including the aforementioned variables, the 
relationship was no longer significant. To perform this analysis we used multivariate 
logistic regression with receipt and non-receipt as the two outcome variables. We did this 
analysis for each of the three dependent variables we analyzed. 
Discussion 
This study was done to determine if rurality affects the probability of receipt of 
ACT for stage III colon cancer patients in North Carolina. First, we wanted to determine 
the overall level of statewide prescription of ACT for stage III colon cancer between 
1998 and 2004. We hoped that the results would indicate whether colon cancer patients in 
North Carolina suffered from under-receipt of treatment. We also hoped that this study 
would add some clarity to the issue of whether patients with colon cancer in rural areas 
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receive differing rates or if region of residence in North Carolina affected the probability 
of ACT receipt. 
Our study was similar to prior studies done byWu and VanEenWyk, but key 
differences do exist between our study and prior studies investigating rurality versus ACT 
receipt for colon cancer. First, our study data is considerably more recent and covers a 
greater time span than previous studies. We used statewide data from 1998 to 2004, while 
the Wu used data from a single year, 2001, and VanEnwyk used data from 1996-1997. 
Consequently, we hoped that our results we provide a more up to date estimate of the 
patterns of ACT receipt for stage III colon cancer patients. Second, the aforementioned 
studies were completed in Louisiana and Washington State respectively, and we felt that 
investigating the relationship between rurality and ACT receipt in North Carolina would 
bemore relevant to our local health systems. 5• 17 Finally, we hoped that including 
additional dependent variables in our study would allow us to make more precise 
conclusions about the patterns of ACT receipt in North Carolina. For example, we 
included variables describing rates of ACT refusal and contraindication which allowed us 
to investigate the relationship between region and rurality and the probability of being 
offered ACT. 
Overall ACT Receipt for Colon Cancer Patients with Stage III Disease 
Ultimately, our results allow us to draw a few conclusions about the treatment of 
colon cancer among North Carolinians. First, nearly forty percent of eligible patients in 
the state still do not receive ACT. This supports prior publications indicating that ACT is 
under prescribed. For example, Scharg et al. and data from the National Cancer Database 
indicate that only 55% and 45% of Stage III colon cancer patients receive ACT 
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respectively. 8• 11 These results highlight the need for continued emphasis on the 
prescription of ACT for all eligible patients in North Carolina. The efforts to improve the 
rates of ACT receipt could take the form of statewide initiatives to make ACT for stage 
III colon cancer patients a measure of cancer treatment quality among all cancer treating 
hospitals in North Carolina. A similar initiative could also be incorporated into the North 
Carolina's Cancer Partnership's overall mission to improve the cancer outcomes among 
state residents. Such an initiative would be worthwhile because data from clinical trials 
suggest that outcomes could improve collectively for all stage III patients if more eligible 
patients received the appropriate treatment. 
Our data also indicate that between 1998 and 2004 there was not clear standard of 
care ACT treatment for followed for eligible patients. Nearly 55.3% of patients only 
received one chemotherapeutic agent. Only 16.6% of patients received multi-drug 
therapy, while for 11% of patients the exact number of drugs used was not recorded. This 
indicates that the current and past standard of care treatments, meaning the treatment 
regimens supported by landmark clinical trials were not used for the majority of patients. 
Those studies support the use of at least two chemotherapeutic agents as a part of ACT. 9• 
10 Again, this is an indication that under treatment was pervasive in the study period, 
and a statewide initiative to improve the level of recommended ACT might be beneficial. 
Rurality vs. ACT Receipt 
Our study results indicate that rural residence does not affect the probability of 
ACT receipt in the North Carolina. The results trended towards higher rates of ACT 
receipt being associated with metropolitan and adjacent to metropolitan areas, but these 
results were not significant on univariate and multivariate analysis. Our other variables 
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of interest, which included the probability of receiving ACT if not contraindicated or 
refused and the probability being offered ACT if not contraindicated, also did not vary 
with rurality significantly. Environment, as defined by rurality, likely has no effect on 
the probability that stage III colon patients in North Carolina receive ACT. It is possible 
that our study did not have enough power to produce a significant test result. Still, the 
absolute difference in probabilities across levels of rurality would not have been 
clinically significant regardless of the p value obtained. The groups differed only slightly 
in regards to the probability of ACT receipt, being offered ACT if not contraindicated, 
and receiving ACT if not contradiccated or refused. 
In addition, it is possible that the OMB-defined urban influence codes did not 
adequately capture rural-urban differences in receipt of ACT. In some cases counties 
were defined as part of a metropolitan area if 25% or more of residents commuted to an 
adjacent metropolitan area, but access to heath care in these counties on the periphery of 
the metropolitan area may in be different from that of counties at the center of the 
metropolitan area. If counties that were actually more rural in character were 
misclassified as urban, differences between rural and urban areas would have been 
obscured. 
Results from prior studies investigating rurality's effect on ACT receipt offered 
conflicting results. VanEwyk found that rurality lowers the probability of ACT receipt for 
stage III colon cancer patients. 5 The most recent data, from our study and from Wu et a!, 
both agree that rurality has no effect.17 Consequently, it possible that over time the 
quality of care available to patients in rural environments in terms of post-operative 
management of stage III colon cancer improved between 1997 and 2001. 
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Region of residence vs. ACT receipt 
Our study also showed that region of residence significantly affects the 
probability of receiving ACT, the probability of being offered ACT and the probability of 
receiving ACT if not refused or contraindicated. This significant difference disappeared 
upon multivariate analysis when race, age, and income were taken into account These 
results indicate that patients receive differing care depending on the region. Patients 
residing in the Asheville, Charlotte and Greenville regions are offered and receive ACT 
much less often than the other regions ofNorth Carolina. This is most likely explained by 
other factors related to each region. Income, race, and age could be confounding the 
relationship between region and ACT receipt Other factors like distance to National 
Cancer Institute funded cancer centers may also act as a confounder in the relationship 
between region and ACT receipt 
There have not been any prior studies investigating region of residence versus 
receipt of ACT for stage III colon cancer. Consequently, there is no body of evidence 
available to substantiate or oppose our findings. Investigating the patterns associated with 
differing quality of cancer treatment in North Carolina is a worthwhile issue. In future 
studies, if the same regions continually have inferior treatment rates for recommended 
cancer treatments, then it would signal for the need of significant interventions to 
improve cancer care in those regions. 
Study Limitations 
The study is hampered by several significant weaknesses. The first group of 
shortcomings relates to the potential for misclassification of treatment and race. For 
example, race in this study was limited to white, black and other. It is likely that these 
classifiers do not accurately represent a significant proportion of the actual study 
population. It is unclear from our system how many patients with colon cancer are 
Hispanic, American Indian or of Asian descent. This is significant because over ten 
percent of the North Carolina population is made up of non-white, non- black races. 21 
Patients of these other races may receive ACT at differing rates, making racial 
misclassification a significant issue. 
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A second potential weakness of our study relates to the method we used to control 
for income. We used mean census tract income as surrogate value for patient income. It is 
difficult to determine how well census tract income represented patient-level data. 
Potentially if patient income is related to the development of colon cancer, then mean 
census tract income would not accurately represent patient income. For example, if 
patients with less income develop colon cancer more often than wealthier patients, then 
the mean census tract income would overestimate patient -level income data. Again, using 
census tract income was a potential source of misclassification of our confounding 
variables and unfortunately we can not predict how this potential error could have 
affected our results. 
Finally, our study's most significant weakness was that we did not have treatment 
data for a large sum of patients in our original sample. The NCCCR did not have 
treatment data for nearly nine hundred patients (16.5%) in the original sample of North 
Carolina residents with Stage III colon cancer. This lack of treatment data potentially 
could have biased our results if these patients were distributed in the state unequally. For 
example if the majority of unknown treatment cases came from rural areas, or from 
specific regions in North Carolina, the exclusion of these cases would alter our results 
significantly if these patients also received ACT at different rates than we found in the 
study. 
Future Research 
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As mentioned earlier this study indicates that patients with stage III colon cancer 
receive ACT less often in the Charlotte, Greenville and Asheville regions. One potential 
confounder of this relationship is patient distance to National Cancer Institute (NCI) 
funded cancer center and patient distance to American College of surgeon certified 
cancer treatment. These centers have to meet specific standards related to cancer 
treatment quality and are monitored closely by state and Federal agencies. American 
college of Surgeon and NCI centers are scattered throughout North Carolina and it is 
possible that patients who live closest to these treatment centers receive ACT at higher 
percentages than patients who live far away. We feel that this is an important question 
that needs to be answered. It may give the medical community in North Carolina more 
insight about how well these centers are performing in delivering care to all patients in 
North Carolina, as well as how distance to these centers relates to region of residence and 
the receipt of recommended ACT receipt for patients in this study. 
Ultimately, the results of this study may mimic those describing the relationship 
between rurality and ACT receipt results. The majority of ACOS treatment centers and 
comprehensive cancer centers are located in metropolitan and or non-
metropolitan/adjacent areas. The close relationship between these variables may indicate 
that they are also closely related in terms of their effect on adjuvant chemotherapy 
receipt. 
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Tables and Figures 
Table 1. 
Outcomes Table of 5 Year Survival for Patients with Stage Ill Colon Cancer 
Mortality figures derived from Moertel et al 1995 
No. of Cases/yr 5 year Mortality 5 year mortality 
with Surgery Alone with ACT and Surgery 
Stage Ill No. Percentage No. Percentage 
22,000 12,100 55% 8066 36.6 
Deaths prevented 
w/ACT 
No. 
4034 
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Table 2. Urban Influence Code (UIC) Groupings 
UIC #ofNC 
Counties 
Metropolitan 40 
1 Large metro area of> 1 million residents 6 
2 Small metro area of< 1 million residents 34 
Metropolitan adjacent 40 
3 Micropolitan area adjacent to large metro area 6 
4 Noncore adjacent to large metro area 1 
5 Micropolitan area adjacent to small metro area 19 
6 Noncore adjacent to small metro area and contains a town of at 9 
least 2,500 residents 
7 Noncore adjacent to small metro area and does not contain a town 6 
of at least 2,500 residents 
Non-metropolitan, non-ad.iacent 19 
8 Micropolitan area not adjacent to a metro area 6 
9 Noncore adjacent to micro area and contains a town of at least 2 
2,500 residents 
10 Noncore adjacent to micro area and does not contain a town of at 4 
least 2,500 residents 
11 Noncore not adjacent to metro or micro area and contains a town 2 
of at least 2,500 residents 
12 Noncore not adjacent to metro or micro area and does not contain 5 
a town of at least 2,500 residents 
Table 3. Demographic Characteristics of Source Population 
Metro Non-metro Non-metro Total 
n(%) Adjacent Non-adjacent n(%) 
n (%) n(%) 
Race 
White 2589 1294 250 4133 
African American 644 331 89 1064 
Other 48 38 6 92 
Sex 
Male 1614 783 159 2556 
Female 1667 880 185 2732 
Mean age 67.57 67.64 68.59 67.66 
Mean income $51,897.38 $42,403.49 $38,451.76 $48,021.02 
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Table 4. Receipt of Adjuvant Chemotherapy: Study Population 
n % 
Chemotherapy administered 2582 58% 
Chemotherapy not administered 1850 42% 
Chemotherapy not recommended 1228 28% 
Chemotherapy contraindicated 68 2% 
Chemotherapy was treatment of choice, not administered, no reason 137 3% 
giVen 
Chemotherapy refused by patient, family member, or guardian 135 3% 
Chemotherapy recommended, unknown if given 282 6% 
Total 4432 
Table 5. Ad.iuvant Ch h emot erapy T reatment c ategones 
n % 
Received adjuvant chemotherapy 2582 58% 
Received adjuvant chemotherapy if not contraindicated or refused 2785 63% 
Offered adjuvant chemotherapy if not contraindicated 3204 72% 
Not offered adjuvant chemotherapy 1228 28% 
Table 6. Receipt of ACT vs. UIC Groupings 
Non-metro Non-metro 
Metro Adjacent Non- x2 Total 
n=2688 n=l448 adjacent n=4417 
n=281 
Receipt of n(%) n(%) n(%) (p value) n(%) 
Chemotherapy 
Received ACT 1585 (59.0) 844 (58.3) 153 (54.4) 1.99 (0.37) 2582 
(58.5%) 
CT if not contraindicated 1713 (63.7) 887 (61.3) 156 (55.5) 3.72 (0.16) 2756 
or refused (62.4%) 
CT if not contraindicated 1959 (72.9) 1033 (71.3) 197 (70.1) 1.77 (0.41) 3189 
(72.2%) 
Not offered ACT 729 (27.1) 415 (28.7) 84 (29.9) 
NA 
1228 (27.8) 
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Table 7. Receipt of ACT by Region of Residence 
Asheville Charlotte Greensboro Greenville Raleigh Wihnington Total X2 
n=430 n=729 n=1373 n=796 n=541 n=569 n=4438 (p 
n(%) n(%) n(%) n(%) n(%) n(%) n(%) value) 
Received ACT 191(44.4) 386(53.0) 861 (62.7) 430 (54.0) 358(66.2) 367 (64.5) 2593(58.4%) 64.9 
(0.0001) 
Received ACT if 211(49.1) 422(57.9) 917 (66.8) 447 (56.2) 373(69.0) 399 (70.1) 27 69( 62.4%) 60.2 
not (0.0001) 
contraindicated 
or refused 
Offered ACT if 273(63.5) 474(65.0) 980 (71.4) 617 (77.6) 414(76.5) 445 (78.2) 3203(72.1%) 61.9 
not (0.0001) 
contraindicated 
Not offered ACT 157(36.5) 255(35.0) 393 (28.6) 179 (22.5) 127(23.5) 124 (21.8) 1235(27.8%) NA 
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Figure 1. NC Cancer Partnership Regions 
Greensboro Raleigh Greenville 
Asheville 
Charlotte 
Wilmington 
Aug~<sl28, 2006 
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